Representative Josh Gottheimer, a prominent Democratic figure from New Jersey, recently executed a significant stock sale involving shares of Coloplast A/S, drawing attention to financial transactions within political circles. This insider trade, disclosed in a filing on June 11th, highlights the intersection of personal investments and public office.
The transaction, specifically involving Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY) stock, occurred on May 14th, with the value of the sold shares ranging between $1,001 and $15,000. This sale was processed through the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account, providing clear details about the nature and scale of the political finance activity.
Examining Coloplast A/S’s market performance reveals the stock opened at $9.22 on a recent Friday. The company has experienced fluctuations, with a one-year low of $9.17 and a one-year high of $14.14, reflecting the dynamic nature of its stock market journey. Its 50-day simple moving average stands at $9.50, while the 200-day simple moving average is $10.27.
From a financial health perspective, Coloplast A/S presents several key ratios. The business maintains a current ratio of 0.95 and a quick ratio of 0.61, indicating its short-term liquidity. Furthermore, its debt-to-equity ratio is reported at 0.98, offering insights into its financial leverage and stability within the investment news landscape.
In addition to stock movements, Coloplast A/S recently declared a dividend, which was distributed to investors on Thursday, May 22nd. Shareholders of record on Monday, May 19th, received a dividend of $0.0389 per share, representing a significant yield of 202.0%. The ex-dividend date for this payout was Friday, May 16th, with the company’s payout ratio currently at 26.67%.
Analyst sentiment regarding CLPBY has seen recent shifts. Barclays adjusted its rating from “strong-buy” to “hold” in early May, followed by Royal Bank of Canada cutting its rating from “moderate buy” to “hold” shortly thereafter. MarketBeat data indicates that, collectively, four equities research analysts have assigned a “hold” rating, while one maintains a “strong buy,” resulting in an average “Hold” rating for the stock.
Representative Josh Gottheimer’s political career is also noteworthy. As a Democratic member representing New Jersey’s 5th Congressional District, he took office on January 3, 2017, with his current term concluding on January 3, 2027. Gottheimer has declared his candidacy for re-election to the U.S. House in 2026 and is also vying for Governor of New Jersey, with the Democratic primary scheduled for June 10, 2025, underscoring his extensive engagement in public service.
Coloplast A/S itself is a global entity dedicated to the development and sale of intimate healthcare products and services. Operating across Denmark, the United States, the United Kingdom, France, and other international markets, the company segments its operations into Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care, showcasing its diverse healthcare portfolio.
